IKT at a glance
Inhibikase Therapeutics, Inc. (IKT, SEC CIK 1750149) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on August 11, 2026, an 8-K current report on September 8, 2026 and Form 4 insider filings as recently as July 31, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2024 (FY2024), Inhibikase Therapeutics, Inc. (IKT) reported revenue of $0 and a net loss of $27.5 million. Diluted EPS was -$1.16.
- As of June 30, 2026, 22 institutional investment managers tracked by SignalX reported holding Inhibikase Therapeutics, Inc. (IKT) shares worth $58.7 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2024
- $0
- 10-K XBRL
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 22 funds
- $58.7M · −1 vs prior quarter
- Latest 8-K
- Sep 8, 2026
- Item 7.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- New regulatory risk: BIOSECURE Act and WuXi AppTec’s June 2026 Section 1260H designation
- Manufacturing concentration: STA Pharmaceutical Hong Kong supplies IKT-001 drug substance and drug product
- Supply-chain disruption: Potential STA designation could require costly, time-consuming manufacturing transition
- Clinical-development risk: Proposed restrictions on China-based clinical data could delay trials or increase costs
- Operational risk: Manufacturing deviations may reduce yields, cause defects, or disrupt clinical-trial supply
AI summary of the IKT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Exhibit 99.1 furnished under Regulation FD, but not deemed filed under Exchange Act Section 18
- Disclosure generally excluded from incorporation by reference into other SEC filings unless expressly referenced
Item EX-99.1: Item EX-99.1
- Phase 3 IMPROVE-PAH enrolling across 26 countries and 46 of 180 planned sites, validating late-stage execution
- IKT-001 targets PAH, a disease with approximately 30% five-year mortality and an estimated $8.3B antiproliferative market
Item 4.01: Changes in Registrant's Certifying Accountant
- CohnReznick dismissed effective August 21, 2026; Deloitte appointed immediately for fiscal 2026
- Prior audit opinions for 2025 and 2024 contained no adverse opinion, disclaimer, or qualification
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results covered quarter ended June 30, 2026
- Press release includes financial results and corporate updates; investors should review Exhibit 99.1 for details
Item EX-99.1: Item EX-99.1
- Q2 2026 net loss $19.6M, or $0.11 per share, versus $9.9M loss prior year
- R&D expense $13.4M, up from $5.3M, reflecting accelerated Phase 3 IMPROVE-PAH development
AI summaries of IKT 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for IKT
Don't miss the next IKT filing
- Alerts as it files. A push when IKT files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut IKT, by share count.
- Ask anything. An AI agent that reads every IKT filing and answers with sources.
IKT alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| BERMAN DENNIS N | M | Jul 30, 2026 | 21,854 | $1.26 |
| BERMAN DENNIS N | M | Jul 30, 2026 | 21,854 | - |
| RA CAPITAL MANAGEMENT, L.P. | J | Jul 29, 2026 | 18,030,000 | - |
| RA CAPITAL MANAGEMENT, L.P. | J | Jul 29, 2026 | 18,030,000 | - |
| Bellini Roberto | A | Jun 26, 2026 | 155,000 | - |
| BERMAN DENNIS N | A | Jun 26, 2026 | 155,000 | - |
| Kush Arvind | A | Jun 26, 2026 | 155,000 | - |
| Munshi Amit | A | Jun 26, 2026 | 155,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $0 | - |
| Operating Income | -$20.1M | -$28.6M | -$52.0M |
| Net Income | -$19.0M | -$27.5M | -$48.3M |
| Balance Sheet | |||
| Total Assets | $14.5M | $98.6M | $181.2M |
| Equity | - | $94.9M | $172.9M |
| ROE | - | -29.0% | -27.9% |
| Per Share | |||
| EPS | $-3.57 | $-1.16 | $-0.49 |
| Cash Flow | |||
| Operating CF | - | -$19.1M | -$27.8M |
| CapEx | $14K | $0 | $13K |
Source: XBRL data in Inhibikase Therapeutics, Inc. (IKT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate IKT share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 22 | $58.7M |
| Q1 2026 | 23 | $43.9M |
| Q4 2025 | 19 | $37.0M |
| Q3 2025 | 17 | $17.0M |
| Q2 2025 | 15 | $19.4M |
| Q1 2025 | 9 | $13.5M |
| Q4 2024 | 6 | $16.8M |
| Q3 2024 | 3 | $39,000 |
- BlackRock+1.46M (+23%)
- Millennium Management+1.10M (+38%)
- Vanguard Capital Management LLC+484.7K (+11%)
- AQR Capital Management+296.2K (+172%)
- State Street Corp+223.3K (+13%)
- Citadel Advisors LLC−1.03M (-93%)
- Bank of America Corp−214.7K (-67%)
- Goldman Sachs Group−99.7K (-67%)
- Morgan Stanley−50.3K (-31%)
- Two Sigma Investments−41.3K (-5%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 114 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
IKT filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Sep 8, 2026 | - | Analysis | - |
| 8-K | Aug 26, 2026 | - | Analysis | - |
| 8-K | Aug 11, 2026 | - | Analysis | - |
| 10-Q | Aug 11, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 31, 2026 | - | - | - |
| 4 | Jul 31, 2026 | - | - | - |
| 8-K | Jul 29, 2026 | - | Analysis | - |
| SC 13G | Jul 28, 2026 | - | - | |
| 8-K | Jul 23, 2026 | - | Analysis | - |
| SC 13G | Jul 17, 2026 | - | - | |
| 8-K | Jul 14, 2026 | - | Analysis | - |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| 8-K | Jun 29, 2026 | - | Analysis | - |
| 8-K | May 12, 2026 | - | Analysis | |
| 10-Q | May 12, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Apr 7, 2026 | - | Analysis | - |
| 8-K | Mar 26, 2026 | - | - | - |
| 10-K | Mar 26, 2026 | Dec 31, 2025 | - | |
| 4 | Feb 24, 2026 | - | - | - |
| 4 | Feb 24, 2026 | - | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
IKT SEC filings: frequently asked questions
Which institutions hold IKT stock?
As of June 30, 2026, the largest Inhibikase Therapeutics, Inc. (IKT) holders among the 13F filers tracked by SignalX were BlackRock ($15.8 million), Blackstone Group ($12.1 million), Vanguard Capital Management LLC ($10.0 million), Millennium Management ($8.2 million), State Street Corp ($3.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was IKT's revenue in fiscal year 2024?
For the fiscal year ended December 31, 2024 (FY2024), Inhibikase Therapeutics, Inc. (IKT) reported revenue of $0 and a net loss of $27.5 million. Diluted EPS was -$1.16. The figures come from the XBRL data in the 10-K.
What did IKT report in its latest 8-K?
Inhibikase Therapeutics, Inc. (IKT) filed an 8-K on September 8, 2026 reporting Item 7.01 (Regulation FD Disclosure). Exhibit 99.1 furnished under Regulation FD, but not deemed filed under Exchange Act Section 18.
What are the latest IKT SEC filings?
Inhibikase Therapeutics, Inc. (IKT) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on August 11, 2026, an 8-K current report on September 8, 2026 and a Form 4 insider filing on July 31, 2026.
What is IKT's SEC CIK number?
Inhibikase Therapeutics, Inc. (IKT)'s SEC Central Index Key (CIK) is 1750149. EDGAR lists every IKT filing under that number.
Ask anything about IKT
The research agent reads IKT's filings, financials, insider trades and 13F holders, then answers with sources.